Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 14;219(9):e20212126. doi: 10.1084/jem.20212126

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Shih et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S5. — Summary information for the 19 monoclonal AIGAs and AMG811. (A and B) Patient distribution and binding characteristics (epitope group, ELISA, Western blot, binding affinity, immunocomplex) and functional impacts (HeLa GAS reporter, HLA-DR expression, IFN-γR1–R2 and IFN-γR2–R2 dimerization, Fc receptor activation, cellular cytotoxicity) of the 20 mAbs indicated in table (A) and heatmap (B). +++, ++, +, − indicate ability, strength, or potency; 1, 2, 3 indicate patient category; X, an absence of measurement in assays. (C) Bar graph for the distribution of the 19 monoclonal AIGAs on the basis of patients and binding sites.